Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2) : a randomised, parallel group, open-label trial
| dc.contributor.author | Muir, Keith W | |
| dc.contributor.author | Ford, Gary A | |
| dc.contributor.author | Ford, Ian | |
| dc.contributor.author | Wardlaw, Joanna M | |
| dc.contributor.author | McConnachie, Alex | |
| dc.contributor.author | Greenlaw, Nicola | |
| dc.contributor.author | Mair, Grant | |
| dc.contributor.author | Sprigg, Nikola | |
| dc.contributor.author | Price, Christopher I | |
| dc.contributor.author | MacLeod, Mary Joan | |
| dc.contributor.author | Dima, Sofia | |
| dc.contributor.author | Venter, Marius | |
| dc.contributor.author | Zhang, Liqun | |
| dc.contributor.author | O’Brien, Eoin | |
| dc.contributor.author | Sanyal, Ranjan | |
| dc.contributor.author | Reid, John | |
| dc.contributor.author | Sztriha, Laszlo K | |
| dc.contributor.author | Haider, Syed | |
| dc.contributor.author | Whiteley, William N | |
| dc.contributor.author | Kennedy, James | |
| dc.contributor.author | Perry, Richard | |
| dc.contributor.author | Lakshmanan, Sekaran | |
| dc.contributor.author | Chakrabarti, Annie | |
| dc.contributor.author | Hassan, Ahamad | |
| dc.contributor.author | Marigold, Richard | |
| dc.contributor.author | Raghunathan, Senthil | |
| dc.contributor.author | Sims, Don | |
| dc.contributor.author | Bhandari, Mohit | |
| dc.contributor.author | Wiggam, Ivan | |
| dc.contributor.author | Rashed, Khalid | |
| dc.contributor.author | Douglass, Chris | |
| dc.contributor.author | ATTEST-2 Investigators | |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.contributor.institution | University of Aberdeen.Cardiometabolic Disease | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Cardiovascular and Diabetes Centre | en |
| dc.contributor.institution | University of Aberdeen.Medical Sciences - Cardiovascular Group | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.date.accessioned | 2024-10-18T10:23:01Z | |
| dc.date.available | 2024-10-18T10:23:01Z | |
| dc.date.issued | 2024-11-30 | |
| dc.description | Acknowledgments The trial was funded by the Stroke Association and British Heart Foundation (grant reference numbers TSA BHF 2015/01 and CS/15/8/32065). Tenecteplase was supplied free of charge by Boehringer Ingelheim. We thank the following individuals: on the Independent Data Monitoring Committee: Richard Lindley (Chair), Graeme MacLennan, and Charlotte Cordonnier. We acknowledge the contributions of key trial support team members: Shirley Mitchell (trial management); Mairi Warren (project and trial management); Alicia Murray (trial management); Angela Welch, Wilma Smith, Emma MacRae, and Wendy Jackson (central outcome assessment); Kirsty Wetherall (statistical checking); John McHugh (database manager); Jane Aziz, Christopher Graham, and Robbie Wilson (electronic data capture and randomisation systems development); Eleni Sakka (imaging database management); Jeb Palmer (University of Edinburgh Systematic Image Review Service oversight); David Perry and David Buchanan (scan housekeeping system); and Lesley Cala, Daisy Mollison, and Elena Boyd (scan reading). | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 10 | |
| dc.format.extent | 650946 | |
| dc.identifier | 297859048 | |
| dc.identifier | 056bdfd4-5ca1-46d9-9d38-49d348d9eaf7 | |
| dc.identifier | 85206342688 | |
| dc.identifier | 39424558 | |
| dc.identifier.citation | Muir, K W, Ford, G A, Ford, I, Wardlaw, J M, McConnachie, A, Greenlaw, N, Mair, G, Sprigg, N, Price, C I, MacLeod, M J, Dima, S, Venter, M, Zhang, L, O’Brien, E, Sanyal, R, Reid, J, Sztriha, L K, Haider, S, Whiteley, W N, Kennedy, J, Perry, R, Lakshmanan, S, Chakrabarti, A, Hassan, A, Marigold, R, Raghunathan, S, Sims, D, Bhandari, M, Wiggam, I, Rashed, K, Douglass, C & ATTEST-2 Investigators 2024, 'Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2) : a randomised, parallel group, open-label trial', The Lancet neurology, vol. 23, no. 11, pp. 1087-1096. https://doi.org/10.1016/S1474-4422(24)00377-6 | en |
| dc.identifier.doi | 10.1016/S1474-4422(24)00377-6 | |
| dc.identifier.iss | 11 | en |
| dc.identifier.issn | 1474-4422 | |
| dc.identifier.other | Bibtex: MUIR20241087 | |
| dc.identifier.other | ORCID: /0000-0003-2115-8184/work/170010490 | |
| dc.identifier.uri | https://hdl.handle.net/2164/24433 | |
| dc.identifier.vol | 23 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | The Lancet neurology | en |
| dc.subject | Substantive connection via an eligible employment contract | en |
| dc.subject | R Medicine | en |
| dc.subject | Other | en |
| dc.subject | CS/15/8/32065 | en |
| dc.subject | TSA BHF 2015/01 | en |
| dc.subject | Supplementary Data | en |
| dc.subject.lcc | R | en |
| dc.title | Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2) : a randomised, parallel group, open-label trial | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Muir_etal_TLN_Tenecteplase_Versus_Alteplase_VoR.pdf
- Size:
- 635.69 KB
- Format:
- Adobe Portable Document Format
